The Medical Advisor

Few nutrition topics generate more heat than seed oils . To some, they are metabolic poison. To others, they are a harmless scapegoat distracting from calories and carbohydrates. As usual, the truth is less dramatic — and more uncomfortable. Seed oils are not a single-variable toxin . They are a metabolic stressor whose impact depends entirely on context . And insulin resistance is the context we keep ignoring. What We Mean by “Seed Oils” Seed oils typically refer to refined vegetable oils high in omega-6 linoleic acid (LA) , including: Soybean oil Corn oil Canola oil Sunflower oil Safflower oil They are: Highly processed Chemically extracted Cheap, shelf-stable Ubiquitous in modern diets They now account for a historically unprecedented share of total calories. The Real Question Isn’t “Are Seed Oils Toxic?” The real question is: How do seed oils behave inside an insulin-resistant metabolic environment? Because physiology changes everything. What is tolerable in a metabolically flexibl...

Introduction Linoleic acid (LA) is the most abundant omega‑6 polyunsaturated fatty acid (PUFA) in modern diets. It is found primarily in seed and vegetable oils such as soybean, corn, sunflower, safflower, and canola oil, as well as in nuts, seeds, and some animal foods. Because industrial food production dramatically increased omega‑6 intake over the past century, linoleic acid has become a focal point of controversy. Some commentators claim it drives inflammation, obesity, metabolic disease, mitochondrial damage, cancer, and cardiovascular disease. This article reviews the best available human evidence, separates mechanistic speculation from clinical reality, and explains how linoleic acid actually fits into a healthy diet. What Is Linoleic Acid? Linoleic acid is an essential fatty acid , meaning the human body cannot synthesize it. It is required for: Cell membrane structure and fluidity Skin barrier function Normal immune signaling Production of longer‑chain fatty acids Deficiency ...

Why Metabolism Is the Missing Link in Modern Medicine Cancer prevention, longevity, and metabolic health are usually discussed as separate domains. Oncology focuses on mutations. Aging research focuses on senescence and epigenetics. Metabolic health is reduced to weight, glucose, or cholesterol. This siloed thinking misses a deeper unifying driver. The common thread connecting cancer risk, cancer outcomes, and biological aging is metabolic signaling —specifically insulin resistance and mitochondrial dysfunction. This article lays out a single, coherent framework: Insulin resistance drives mitochondrial dysfunction, which erodes metabolic flexibility. That environment accelerates aging and creates fertile ground for cancer. 1. Insulin Resistance Is Not a Blood Sugar Problem Insulin resistance (IR) is often framed as a pre-diabetic condition. In reality, it is a whole-cell signaling disorder . When insulin signaling is impaired: Cells fail to take up glucose efficiently Circulating insul...

Introduction The potential applications of Ivermectin and Benzimidazole (Fenbendazole and Mebendazole) in cancer treatment have sparked significant interest online, with growing communities exploring these compounds for therapeutic use. While both have roots in anti-parasitic medicine, emerging research and anecdotal evidence suggest they may offer benefits in combating colorectal cancers. The main goal with this article is to provide as much clear information as possible for someone dealing with colorectal cancer. This article deals with the basis and practical approach to using Fenbendazole and Ivermectin for colorectal cancer. Can Fenbendazole and Ivermectin play a key role in treating Stage 4 Colorectal Cancer? Several peer-reviewed papers and case studies (below) strongly suggest that it might: Ivermectin, Fenbendazole and Mebendazole in Cancer: 2024 Peer-Reviewed Protocol in Cancer Ivermect...